Optimizing Immunotherapy in Lung Cancer – OncLive
OncLive |
Optimizing Immunotherapy in Lung Cancer
OncLive OncLive: Can you give an overview of your presentation? Denham: My topic lays the groundwork for a lot of the others—it is the use of immunotherapy, largely anti–PD-1 therapy, for NSCLC. I reviewed the pivotal trials that have demonstrated that this … |
